Cancer Targeted Technology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Cancer Targeted Technology is a private, clinical-stage biotech developing a pipeline of small molecule theranostics for prostate cancer. Its lead programs include a PSMA-targeted PET imaging agent (CTT1057) and a radiotherapeutic (CTT1403), with an IND already filed for the latter. The company operates a platform-based business model, is pre-revenue, and has secured non-dilutive grant funding, including a recent $2.4M Fast Track grant, to advance its targeted drug conjugate programs.

Prostate Cancer

Technology Platform

Proprietary platform for designing small molecule theranostics that target enzymes (e.g., PSMA) for both diagnostic imaging and therapeutic delivery.

Opportunities

The validated and growing market for PSMA-targeted theranostics in prostate cancer presents a major opportunity.

CTT's small molecule platform could offer manufacturing or pharmacological advantages over peptide-based competitors.

Recent non-dilutive grant funding ($2.4M Fast Track) provides capital to advance its novel drug conjugate program.

Risk Factors

Intense competition from large pharma and other biotechs in the PSMA space poses a significant commercial risk.

The high failure rate inherent in drug development represents a major clinical and regulatory risk.

As a private, pre-revenue company, securing sufficient funding to advance multiple programs through clinical trials is a persistent execution risk.

Competitive Landscape

CTT operates in the highly competitive field of PSMA-targeted agents, competing directly with Novartis's approved therapy Pluvicto and diagnostic Locametz, as well as numerous clinical-stage programs from other companies. Its differentiation is based on its proprietary small molecule scaffold, which it hopes will offer benefits in stability, cost, or targeting compared to peptide-based approaches. Success depends on demonstrating superior clinical profiles.

More companies in Small Molecule Drugs →More companies in United States →